Suppliers and packagers for VASCEPA

VASCEPA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057	NDA	Amarin Pharma Inc.	52937-001-20	120 CAPSULE in 1 BOTTLE (52937-001-20)	2012-10-01
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057	NDA	Amarin Pharma Inc.	52937-003-16	1 BLISTER PACK in 1 CARTON (52937-003-16) / 16 CAPSULE in 1 BLISTER PACK	2016-09-16
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057	NDA	Amarin Pharma Inc.	52937-003-40	240 CAPSULE in 1 BOTTLE (52937-003-40)	2016-09-16
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057	NDA	Amarin Pharma Inc.	52937-005-20	120 CAPSULE in 1 BOTTLE (52937-005-20)	2025-12-22

Vascepa (Icosapent Ethyl) Supplier Landscape

Last updated: February 19, 2026

Icosapent ethyl, marketed as Vascepa, is a prescription-grade omega-3 fatty acid used to reduce cardiovascular risk. Its active pharmaceutical ingredient (API) is highly purified eicosapentaenoic acid (EPA). The manufacturing and supply chain for Vascepa are critical to its market availability and affordability. Key components of this supply chain involve API synthesis, formulation, and distribution, with specific patents and regulatory approvals governing these processes.

What are the primary suppliers of icosapent ethyl API?

The synthesis of highly purified icosapent ethyl API is a specialized process. While the exact details of every supplier are proprietary and subject to change, the primary manufacturing entity historically associated with Vascepa's API is Amarex Clinical Research GmbH. Amarex, a German company, has been integral in the development and supply of the API for Vascepa.

Beyond the direct API manufacturer, secondary suppliers for raw materials and intermediates are essential. These can include companies specializing in:

• Fish oil extraction and purification: Sourcing of crude fish oil rich in omega-3 fatty acids.
• Chemical synthesis and esterification: The complex process of isolating EPA and converting it into its ethyl ester form.
• Quality control and analytical services: Ensuring the purity and potency of the API meet stringent pharmaceutical standards.

While Amarex has been a consistent supplier, the pharmaceutical industry often diversifies its supply chain to mitigate risks. This can involve qualifying additional API manufacturers or relying on contract manufacturing organizations (CMOs) under specific agreements with the drug's marketer.

What is the patented intellectual property landscape surrounding Vascepa?

The intellectual property protecting Vascepa is multifaceted, encompassing patents on the API itself, its purification methods, specific formulations, and methods of use for treating cardiovascular conditions. These patents have been crucial in defining the drug's market exclusivity.

Key Patent Areas:

• Composition of Matter Patents: These patents cover the icosapent ethyl molecule.
  • U.S. Patent No. 5,965,553, originally assigned to Marrow Pharmaceuticals, Inc. (later acquired by Kowa Company, Ltd.), claimed icosapentaenoic acid ethyl ester [1]. This patent has expired.
• Method of Purification Patents: Significant innovation lies in achieving the high purity (>96%) of EPA ethyl ester required for Vascepa.
  • U.S. Patent No. 8,450,513, assigned to Amarin Pharmaceuticals Ireland Limited (the current marketer of Vascepa), describes a method for purifying EPA ethyl ester. This patent was a key point of litigation in the Vascepa patent landscape, with challenges seeking to invalidate its claims of inventiveness regarding purification techniques [2].
• Method of Use Patents: These patents protect the specific therapeutic applications of icosapent ethyl, particularly in cardiovascular risk reduction.
  • U.S. Patent No. 8,999,960, assigned to Amarin Pharmaceuticals Ireland Limited, claims a method for reducing the risk of myocardial infarction and stroke in patients with elevated triglyceride levels and established cardiovascular disease or diabetes with other risk factors, using icosapent ethyl [3]. This patent was also subject to significant legal challenges by generic manufacturers.
  • U.S. Patent No. 9,107,777, also assigned to Amarin Pharmaceuticals Ireland Limited, covers a method for reducing the risk of ischemic events in specific patient populations [4].

Litigation and Exclusivity:

The exclusivity of Vascepa has been fiercely defended. Amarin Corporation, the developer and marketer of Vascepa, has engaged in extensive litigation to uphold its patents. A significant legal battle involved challenges to the validity of patents, particularly U.S. Patent No. 8,450,513, by generic drug manufacturers seeking to enter the market.

In 2019, a U.S. federal court invalidated key patents (including U.S. Patent No. 8,999,960) covering Vascepa's use in reducing cardiovascular risk. This ruling opened the door for generic versions of icosapent ethyl. However, Amarin appealed this decision. The U.S. Court of Appeals for the Federal Circuit later reversed the district court's decision, reinstating the validity of the patents for a period. This legal back-and-forth significantly impacted market entry timelines for generic competitors [5, 6].

Despite these patent protections, the market for icosapent ethyl has seen and will continue to see increased competition as patents expire or are successfully challenged.

Who are the current marketers and distributors of Vascepa?

Amarin Corporation Plc is the primary marketer and distributor of Vascepa. Amarin has historically held the exclusive rights to market and sell Vascepa in key global markets, including the United States, Canada, and various European countries.

Key Commercial Activities:

• United States Market: Amarin has been the sole marketer of Vascepa in the U.S. following its FDA approval. The drug's approval was based on the REDUCE-IT trial, demonstrating its efficacy in reducing cardiovascular events [7].
• Global Expansion: Amarin has pursued global regulatory approvals and commercialization efforts in Canada, the European Union, and other regions. This often involves partnerships or licensing agreements with local pharmaceutical companies for distribution in specific territories.
• Distribution Network: Amarin utilizes a network of wholesale distributors, specialty pharmacies, and direct-to-pharmacy channels to ensure Vascepa reaches patients.

Impact of Generic Entry:

The successful or impending entry of generic versions of icosapent ethyl will alter the marketing and distribution landscape. Generic manufacturers, upon patent expiry or successful invalidation, will establish their own distribution channels, directly competing with Amarin. This will likely lead to price reductions and a broader availability of the icosapent ethyl product.

What are the regulatory requirements for supplying icosapent ethyl?

Supplying icosapent ethyl, whether as an API or finished drug product, is subject to stringent regulatory oversight by health authorities worldwide. The primary objective is to ensure the safety, efficacy, and quality of the medication.

Key Regulatory Bodies and Requirements:

• U.S. Food and Drug Administration (FDA):
  • Good Manufacturing Practices (GMP): API manufacturers and finished product manufacturers must adhere to cGMP regulations. This includes requirements for facilities, equipment, personnel, quality control, and documentation.
  • Drug Master File (DMF): API manufacturers typically file a DMF with the FDA, which contains detailed information about the manufacturing process, facilities, and quality controls. The drug product applicant (e.g., Amarin or a generic manufacturer) references this DMF in their New Drug Application (NDA) or Abbreviated New Drug Application (ANDA).
  • ANDA for Generics: Generic manufacturers must submit an ANDA, demonstrating bioequivalence to Vascepa and adherence to all applicable GMP standards.
  • Labeling and Packaging: Strict requirements govern the labeling and packaging of pharmaceuticals to ensure correct dosage, indications, warnings, and patient information.
• European Medicines Agency (EMA) and National Competent Authorities (NCAs) in EU Member States:
  • Manufacturing Authorisation: Facilities manufacturing APIs and finished products within the EU must hold a manufacturing authorisation.
  • Certificate of Suitability (CEP): For APIs, a CEP issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) is often required, demonstrating compliance with European Pharmacopoeia standards.
  • Marketing Authorisation Application (MAA): Similar to the FDA's NDA, an MAA is required for placing a drug on the market in the EU.
• Other International Regulatory Agencies: Agencies in countries like Japan (PMDA), Canada (Health Canada), and Australia (TGA) have their own specific requirements, often harmonized with FDA and EMA standards but with unique nuances.

Quality Control and Purity Standards:

• Purity: Icosapent ethyl API must meet a high purity threshold (typically >96% EPA ethyl ester) as defined in pharmacopoeial monographs (e.g., United States Pharmacopeia - USP).
• Impurities: Strict limits are placed on various impurities, including other fatty acids, residual solvents, and degradation products.
• Stability: The API and finished product must demonstrate adequate stability under defined storage conditions to ensure shelf life.

Supply Chain Integrity:

Regulators increasingly focus on supply chain security to prevent counterfeiting and ensure product integrity from manufacturing to the patient. This involves rigorous tracking, tracing, and serialization requirements.

What are the potential impacts of generic competition on Vascepa's supply chain?

The advent of generic competition for Vascepa has significant implications for its entire supply chain, from API manufacturing to final distribution.

Impacts on API Supply:

• Increased API Manufacturing Volume: Multiple generic manufacturers will require access to icosapent ethyl API, leading to an increased demand.
• Diversification of API Suppliers: Generic companies may seek to qualify new API suppliers beyond Amarex's historical partners to ensure competitive pricing and secure supply. This could involve CMOs with expertise in esterification and high-purity omega-3 production.
• Price Pressure on API: Increased competition among API suppliers and negotiation leverage from multiple generic buyers will likely drive down API prices.
• Focus on Cost-Effective Production: Generic manufacturers will prioritize API suppliers capable of producing the molecule at a lower cost while meeting stringent quality standards.

Impacts on Formulation and Finished Product Manufacturing:

• Multiple CMOs: Generic companies may rely on CMOs for the formulation and final packaging of their icosapent ethyl products, potentially increasing the number of contract manufacturers involved.
• Capacity Planning: The collective demand from multiple generic brands will require careful capacity planning from CMOs and packaging suppliers.
• Quality Assurance Scrutiny: Regulatory bodies will maintain a high level of scrutiny on all manufacturers, both originator and generic, to ensure consistent quality and compliance.

Impacts on Distribution and Logistics:

• Broader Distribution Networks: Generic companies will establish their own distribution channels, potentially utilizing a wider array of wholesalers, specialty pharmacies, and direct-to-patient services.
• Inventory Management: Managing inventory across multiple brands and suppliers will become more complex.
• Price Wars and Market Share: Competition will likely lead to aggressive pricing strategies, affecting the overall revenue generated by icosapent ethyl products. This could lead to consolidation among suppliers if profit margins shrink significantly.

Impacts on Amarin:

• Reduced Market Share and Revenue: Amarin will experience a decline in its market share and revenue for Vascepa as generic alternatives become available.
• Focus on New Products or Indications: Amarin may shift its focus to developing new drug candidates or exploring additional indications for existing products to offset the impact of generic competition.
• Continued Litigation/Patent Defense: While key patents may have expired or been litigated, Amarin might continue to defend any remaining intellectual property or explore legal avenues related to market entry.

The transition to a multi-player market necessitates a robust and adaptable supply chain capable of meeting diverse quality, volume, and cost demands.

Key Takeaways

• Amarex Clinical Research GmbH is a primary historical supplier of the icosapent ethyl API.
• Vascepa's intellectual property portfolio includes patents on the API, purification methods, and methods of use, which have been subject to significant litigation.
• Amarin Corporation Plc is the primary marketer and distributor of Vascepa globally.
• Supplying icosapent ethyl requires adherence to strict regulatory standards, including GMP, from agencies like the FDA and EMA.
• Generic competition is expected to increase demand for API, diversify suppliers, and exert downward pressure on prices across the supply chain.

Frequently Asked Questions

What is the specific chemical name for the active ingredient in Vascepa?

The active ingredient in Vascepa is icosapent ethyl.

Are there other branded omega-3 fatty acid drugs on the market with similar indications?

Yes, other branded omega-3 fatty acid prescription drugs exist, such as Epanova (omega-3-carboxylic acids) and Lovaza (omega-3-ethyl esters), though they may have different approved indications and efficacy profiles.

Can individuals obtain icosapent ethyl without a prescription?

No, icosapent ethyl (Vascepa) is a prescription-only medication.

What is the primary source of the EPA used in icosapent ethyl production?

The EPA is derived from fish oil, which undergoes extensive purification and chemical processing to isolate and esterify the EPA.

How does the purity of icosapent ethyl API compare to over-the-counter fish oil supplements?

Vascepa's icosapent ethyl API is highly purified, typically exceeding 96% EPA ethyl ester, and manufactured under strict pharmaceutical GMP. Over-the-counter fish oil supplements generally have lower purity, contain a mixture of omega-3 fatty acids, and are not subject to the same rigorous pharmaceutical manufacturing and regulatory standards.

What is bioequivalence in the context of generic Vascepa?

Bioequivalence means that a generic drug product delivers the same amount of active ingredient into the bloodstream over the same period as the reference listed drug (Vascepa). This is demonstrated through pharmacokinetic studies and ensures the generic is therapeutically equivalent.

Citations

[1] U.S. Patent No. 5,965,553 A. (1999). Eicosapentaenoic acid ethyl ester. Google Patents. [2] U.S. Patent No. 8,450,513 B2. (2013). Method for purifying ethyl eicosapentaenoate. Google Patents. [3] U.S. Patent No. 8,999,960 B2. (2015). Method for reducing the risk of myocardial infarction and stroke. Google Patents. [4] U.S. Patent No. 9,107,777 B2. (2015). Method for reducing the risk of ischemic events. Google Patents. [5] Amarin Corporation Plc. (2019, October 17). Amarin’s Vascepa® (icosapent ethyl) patent litigation update. Amarin Investor Relations. [6] Amarin Corporation Plc. (2020, July 2). Amarin Announces Federal Circuit Decision Reversing District Court Ruling in Vascepa® Patent Litigation. Amarin Investor Relations. [7] Bhatt, D. L., et al. (2019). Cardiovascular Risk Reduction with 4 g Daily of Icosapent Ethyl in High-Risk Patients with Hypertriglyceridemia. New England Journal of Medicine, 380(1), 11–22. https://doi.org/10.1056/nejmoa1812792